02:04 PM EST, 02/03/2026 (MT Newswires) -- Sanofi ( SNY ) said Tuesday that Rezurock, or belumosudil, has been added to the provincial formularies in Canada's British Columbia and Ontario for adult and pediatric patients aged 12 and older with chronic graft-versus-host disease, or GVHD, who have not responded to at least two prior systemic therapies.

This follows Rezurock's coverage in Quebec since November 2025, the company said, adding that full reimbursement criteria are available on provincial and Canada Drug Agency websites.

Chronic GVHD is a serious complication that can occur after a stem cell transplant, when donor cells attack the patient's body, the company said.

Price: 47.46, Change: +0.19, Percent Change: +0.40